Menu
Search
|

Menu

Close
X

Surface Oncology Inc SURF.OQ (NASDAQ Stock Exchange Global Market)

4.40 USD
-0.19 (-4.14%)
As of Feb 22
chart
Previous Close 4.59
Open 4.62
Volume 29,443
3m Avg Volume 39,279
Today’s High 4.62
Today’s Low 4.30
52 Week High 18.11
52 Week Low 3.47
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
95
FY17
13
FY16
2
EPS (USD)
FY18
0.169
FY17
-1.717
FY16
-0.257
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.70
Price to Sales (TTM)
vs sector
--
6.29
Price to Book (MRQ)
vs sector
--
5.26
Price to Cash Flow (TTM)
vs sector
--
24.98
Total Debt to Equity (MRQ)
vs sector
--
16.12
LT Debt to Equity (MRQ)
vs sector
--
11.38
Return on Investment (TTM)
vs sector
--
14.45
Return on Equity (TTM)
vs sector
--
15.96

EXECUTIVE LEADERSHIP

Daniel Lynch
Executive Chairman of the Board, Since 2017
Salary: --
Bonus: --
J. Jeffrey Goater
President, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
David Grayzel
Co-Founder, Director, Since 2017
Salary: --
Bonus: --
Jessica Fees
Principal Financial Officer, Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Scott Chappel
Chief Technology Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

50 Hampshire St Fl 8
CAMBRIDGE   MA   02139-1548

Phone: +1617.7144096

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system, to block the activity of a range of suppressor cells in the tumor microenvironment, and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity, it hopes to expand the reach of cancer immunotherapy to patients in need of treatment.

SPONSORED STORIES